Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9
- Drug Discovery
- Medical Info
- Data Management
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 148361
– the sole and exclusive worldwide right and license, with no right to sublicense under both the Licensors Technology and interest in any Joint Technology, to use the Licensor Transporters for the identification and/or development of Lead Compounds and Collaboration Products in the Field of Use;
– the sole and exclusive worldwide right and license, with the right to sublicense to Affiliates of Licensee and/or one or more Third Parties, under both the Licensor Technology and interest in any Joint Technology, to make, have made, use, import, market, offer for sale and sell Lead Compounds and Collaboration Products in the Field of Use;
– during the term of the Research Program, the sole and exclusive right and license, with no right to sublicense, under both the Licensor Ancillary Transporter Technology and interest in any Joint Technology, to use the Licensor Ancillary Transporters for the sole purpose of conducting selectivity testing of Lead Compounds and Collaboration Products;
– after the term of the Research Program, a non-exclusive right and license, with no right to sublicense, under the Licensor Ancillary Transporter Technology to use the Licensor Ancillary Transporters for the sole purpose of conducting selectivity testing of Lead Compounds and Collaboration Products;
– during the term of this Agreement, a nonexclusive right and license, with no right to sublicense, to use all data and information generated by or on behalf of Licensor in the conduct of the Research Program, including data relating to Hits in the Licensor Proprietary Chemical Library, but only as shall be reasonably necessary for Licensee to conduct research to identify and develop Lead Compounds and Collaboration Products, provided, however, that such license shall become sole and exclusive when a Compound is designated a Lead Compound in accordance with Article Six and shall revert to a non-exclusive license upon determination of the Steering Committee or Licensee that such Lead Compound will not become a Collaboration Product;
– during the term of this Agreement, an exclusive right and license, with the right to sublicense, to use all data and information generated by or on behalf of Licensor in the conduct of the Research Program relating to Lead Compounds and/or Collaboration Products in the Licensor Proprietary Chemical Library, but only as shall be reasonably necessary for Licensee to conduct research to identify and develop Lead Compounds and Collaboration Products; and
– during the term of this Agreement, a non-exclusive right and license, with no right to sublicense, to use the Licensor Materials but only to the extent that such right and license shall be necessary for Licensee to identify and develop Lead Compounds and Collaboration Products.
Glutamate transporters are a family of neurotransmitter transporter proteins that move glutamate – the principal excitatory neurotransmitter – across a membrane.
Licensor Transporters mean EAAT-2 and EAAT-3 protein of amino-acid compositions.
IPSCIO Record ID: 223154
For the License Under All Licensor Research Program Patents, Licensor grants a non-exclusive license in the Field under all Research Program Patents owned by Licensor to the extent such patents cover making, using, selling, offering for sale or importing a Qualified Lead Compound, an Active Compound or a Licensed Product.
DirectedDiversityÂ® Chemical Library means a computer-generated library of compounds containing integrated structureâ€¢activity and synthesis data.
Active Compound means a Qualified Lead Compound or a compound derived from a Qualified Lead Compound that has been formally selected by Licensee after recommendation by the Research Steering Committee for preclinical development as evidenced by initiation of a Licensee supported range finding toxicology study to be performed by the Licensee Toxicology Department or its designate.
The Licensed Product means any commercial product containing an Active Compound.
Licensor Accessible Libraries means anyDirectedDiversityÂ® Chemical Library that is generated by Licensor outside of the Research Program.
IPSCIO Record ID: 223145
This DiscoverWorksâ„¢ agreement is a research and development collaboration to identify Initial Hits, Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds active against selected targets, and suitable, if required, for medicinal chemistry optimization, that may be developed and commercialized.
Licensed Product means any commercial product containing an Active Compound as an active ingredient.
Active Compound means a Program Lead Compound or a Pre-Clinical Lead Compound identified in the course of the Research Program, or compound further optimized from such a Program Lead Compound or a Pre-Clinical Lead Compound.
Chemical Optimization means the design, synthesis and identification of Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds using DiscoverWorksâ„¢ Technology and other technologies.
DiscoverWorksâ„¢ Technology means DirectedDiversityÂ® Technology and ThermoFluorÂ® Technology.
DirectedDiversity(R) Technology means the descriptions, figures and claims of the Patent Rights and associated proprietary Licensor Know-how used to identify potential therapeutic compounds.
ThermoFluorÂ® Technology means the Patent Rights and associated proprietary Licensor Know-how used to evaluate ligand-binding parameters.
IPSCIO Record ID: 222558
For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.
For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.
For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.
Product means any Agreement Product or Licensees Product.
Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.
Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.
Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.
Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'
IPSCIO Record ID: 237211
For License to Licensor Leads, Collaboration Leads and Licensee Leads, Licensor grants an exclusive worldwide license, with the right to grant sublicenses, to use the Licensor Leads, Collaboration Leads and Licensee Leads and Collaboration Results pursuant to a Collaboration Project or a Licensee Project to research, develop, make, have made, use, import and have sold Licensed Products in the Diagnostic Imaging Field.
For the Option in the Licensee Therapeutics Field, the License Option, with regard to any Licensor Lead for which a Collaboration Project exists and for any Collaboration Lead or Licensee Lead, Licensee may extend the license rights granted to the exclusive use of such lead to research, develop, make, have made, use, import and have sold Licensed Products in the Licensee Therapeutics Field and will have a non-exclusive license to use the Licensor Technology in the Licensee Therapeutics Field in connection therewith; provided that such lead is not part of an active Licensor research and development program or that Licensor is not precluded from granting the license because of an agreement with a third party.
Licensor Technology shall mean collectively any proprietary peptide, protein and antibody library technology and/or all related materials, data, know-how, inventions and Patent Rights that Licensor owns or controls and has the right to grant licenses to in the Diagnostic Imaging Field existing or arising during and through the Research Term.
Licensor Leads shall mean any peptide, protein or antibody molecules existing as of the Effective Date, including Proteases, Antibodies, Blood Proteins , Cell Surface ReceptorsÂ·, Signal Transduction Components, and, Viruses, and any peptide, protein or antibody molecules that Licensor thereafter owns or controls and has the right to grant licenses in the Diagnostic Imaging Field after the Effective Date for so long as Licensee maintains the exclusive license to the Licensor Technology in the Diagnostic Imaging Field, and any data, know-how, inventions and Patent Rights pertaining to such Licensor Leads. Licensor Leads shall not include any Collaboration Leads.
Collaboration Leads shall mean any peptide, protein or antibody molecule and the sequence contained therein and derivatives thereof, resulting from or pertaining to any Collaboration Project commenced during the Research Term and that exist at the time of termination of the Research Term and associated Patent Rights, other than Licensor Leads.
Licensee Leads shall mean any peptide, protein or antibody molecule and the sequence contained therein and derivatives thereof discovered by Licensee after the Research Term using any of the Licensor Technology or Licensor Improvements and associated Patent Rights.
Collaboration Results shall mean any Collaboration Leads and other materials, information, data, and know-how, whether or not patentable, that result from any Collaboration Project that is useful by Licensee in the Collaboration Field or by Licensor in all fields except the Collaboration Field, and any Patent Rights covering inventions resulting from such Collaboration Project, excluding Licensor Technology and Licensor Improvements and Barriers Carrier and Licensee Improvements.
Licensed Product shall mean any product that consists of, includes or was derived from any Licensor Lead, Collaboration Lead or Licensee Lead for which Formal Development has commenced or which arose out of a Collaboration Project.
Diagnostic Imaging Field shall mean any in vivo use in medical imaging, including radiopharmaceutical, ultrasound, MRI and X-ray and light imaging.
Licensee possesses intellectual property, technology and expertise relating to the research, development and commercialization of diagnostic imaging products and radiopharmaceuticals.
IPSCIO Record ID: 249766
Licensor Intellectual Property means, individually and collectively, all Inventions that are conceived, discovered, developed, generated, created, made or reduced to practice or tangible medium of expression solely by employees or consultants of Licensor at any time prior to the Effective Date or after the Effective Date; any tangible materials provided by Licensor to Licensee for use in the conduct of the Program, together with, where applicable, any analogs, derivatives, fragments, progeny, sub-cellular constituents or expression products thereof; and the NeoMorph Screening Library, the NeoMorph Focused Libraries, ALIS and QSCD. The Licensor Intellectual Property, however, does not include any know-how, processes, information and data which is, as of the Effective Date or later becomes, generally available to the public.
Derivative Compounds means any analog, homolog or isomer of a Lead Compound, which has an IC50 value against the Screening Target of twenty (20) micromolar or less, which results from a chemical synthesis program based on the Lead Compounds or is based on structure-activity data of the Lead Compound; provided, that any such program or data is in respect of a target protein from other bacterial or fungal organisms homologous in origin and biological function to the original Screening Target.
IPSCIO Record ID: 291205
Licensor grants a worldwide, exclusive license, with right to sublicense, in the Field under such patent to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, provided that Licensor is not contractually prohibited under a written agreement with a third party from granting such an exclusive license. In the event that Licensor is so contractually prohibited from granting such an exclusive license, Licensor shall grant to Licensee as broad a scope of license as it is permitted (for example, a non-exclusive license) and Licensor shall use its reasonable best efforts to negotiate with such third party to remove such contractual prohibition so as to allow Licensor to grant Licensee the foregoing exclusive license under such Licensor Patents.
For the Unblocking License Grant – Licensor grants a worldwide, nonexclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensor Compounds, Derivative Compounds, and Licensed Products, under any Licensor patent rights which would otherwise be infringed by Licensee but for this license.
DirectedDiversity Technology means Licensor Patents and proprietary know-how that relate to generating and utilizing a DirectedDiversity Chemical Library.
DirectedDiversity(R) Chemi-Informatic Technology uses proprietary computer algorithms to design, select and iteratively refine combinatorial libraries of novel, small-molecule drugs based on screening hits obtained from Licensor or other screening libraries, target-protein 3D structures, or pharmacophore models derived from lead compounds.
Active Compound means a Licensor Compound or Derivative Compound that has been formally selected by Licensee for preclinical and/or clinical development.
Licensee is engaged in research and development of human therapeutic products. The purpose of this collaboration is to identify qualified lead compounds active against selected targets and suitable for medicinal chemistry optimization that may be developed and commercialized by Licensee.
IPSCIO Record ID: 203459
This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.
The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.
The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.
The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.
The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.
IPSCIO Record ID: 211864
GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.
GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.
The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient. The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.
This agreement pertains to drug discovery.